MPS2 Scores Show Strong Consistency in Both DRE and Non-DRE Urine Samples
Lynx Dx, a leader in innovative diagnostic solutions, has announced the publication of a comprehensive analytical validation study for its flagship test, MyProstateScore 2.0 (MPS2), in the peer-reviewed journal Diagnostics. The study confirms MPS2’s strong analytical performance in detecting prostate cancer biomarkers from both post-digital rectal exam (DRE) and non-DRE urine sample solidifying MPS2’s utility across in-office and at-home testing settings.
This latest publication builds on previous clinical validation research, including a 2024 study in JAMA Oncology and a 2025 study in the Journal of Urology, both of which showed that MPS2 significantly outperforms PSA-based screening and traditional clinical factor models in identifying patients at risk for clinically significant prostate cancer.
According to Dr. Spencer Heaton, Chief Medical Officer at Lynx Dx, "This study reinforces the value of MPS2 as a non-invasive diagnostic tool that delivers consistent and precise results. By demonstrating robust analytical performance, MPS2 continues to be validated as a reliable option for prostate cancer risk assessment across diverse clinical workflows."
MPS2 is a urine-based test that measures 18 prostate cancer-related biomarkers to assess a man's risk of harboring clinically significant prostate cancer. The analytical validation showed that all 18 biomarkers met stringent criteria for linearity, precision, and detection sensitivity.
The study, which was based on Clinical Laboratory & Standards Institute guidelines, also confirmed high reproducibility of MPS2 scores and analyte detection with minimal interference from common urinary substances—demonstrating the test's reliability in real-world conditions.
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing expression of 18 unique gene transcripts, including the T2:ERG gene fusion, the most specific biomarker for prostate cancer. The test optimizes diagnostic accuracy for both biopsy naïve patients and those with a prior negative biopsy. Additionally, it provides diagnostic flexibility with optional assessment of personalized risk factors known to influence the development of clinically significant prostate cancer.